CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health.
Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.
Company Details
- Employees
- 2
- Address
- 2 Rue Ambroise Paré, Paris,75010,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.celescreen.com/
- Keywords
- toxicology, systemic toxicity, reprotoxicity, teratogenicity, REACH, drug design, lead optimization, C. elegans.
- HQ
- Paris
Celescreen Questions
Celescreen's website is http://www.celescreen.com/
Celescreen's LinkedIn profile is https://fr.linkedin.com/company/celescreen
Celescreen has
2 employees.
View email and phone details for 2
employees at Celescreen.
Celescreen's industry is
Biotechnology Research
Celescreen's top competitors are
Celesc - Centrais Elétricas De Santa Catarina,
Dreampore,
Refeyn,
Sicom,
Socicam Aeroportos & Aeroporto De Chapecó,
Biosignis,
Miltenyi Biotec,
Aeroporto Municipal Serafim Enzo Bertazzo,
Natalie Setareh,
Celescape.
Celescreen's categories are Biotechnology Research
